Tetrylammonium

Tetrylammonium

SCHEMBL4332463

C=C(C)C(N)=O.CC[N+](CC)(CC)CC.[Cl-]

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Tetrylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.60
PMP22 Q01453 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ATM Q13315 1/20 0.45
TSHR P16473 4/20 0.43
NFKB1 P19838 1/20 0.40
KCNA1 Q09470 1/20 0.40
THRB P10828 1/20 0.34
LMNA P02545 1/20 0.33
ALOX15 P16050 1/20 0.33
BLM P54132 1/20 0.33
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrylammonium SCHEMBL28754153 0.97 TDP1 (0.63) TDP1PMP22KDM4EATMTSHR
Hydrochloric Acid SCHEMBL662253 0.87 TDP1 (0.50) TDP1PMP22KDM4EATMTSHR
Hydrochloric Acid SCHEMBL605741 0.85 TDP1 (0.60) TDP1PMP22ATMTSHRTHRB
Tetrylammonium SCHEMBL29209200 0.84 PMP22 (0.56) TDP1PMP22KDM4EATMTSHR
Hydrochloric Acid SCHEMBL27980318 0.83 TDP1 (0.57) TDP1PMP22ATMTSHRTHRB
Water SCHEMBL29010291 0.83 TDP1 (0.57) TDP1PMP22ATMTSHRTHRB
SCHEMBL4969427 0.82 TDP1 (0.63) TDP1PMP22ATMTSHRTHRB
Tetrylammonium SCHEMBL27921045 0.82 ATM (0.47) TDP1PMP22KDM4EATMTSHR
Propane SCHEMBL22974974 0.81
Propane SCHEMBL28309137 0.81 TDP1 (0.80) TDP1PMP22TSHRTHRBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598290-B2 Cytotoxic agents comprising new C-2 modified taxanes IMMUNOGEN, INC. (US) 2009-10-06 US claimed
US-20070270482-A1 Cytotoxic Agents Comprising New C-2 Modified Taxanes AVENTIS PHARMA S.A. (FR) 2007-11-22 US claimed
EP-1819687-A2 CYTOTOXIC AGENTS COMPRISING NEW C-2 MODIFIED TAXANES Aventis Pharma S.A. (FR) 2007-08-22 EP claimed
EP-1688415-A1 Cytotoxic agents comprising new C-2 modified taxanes Aventis Pharma S.A. (FR) 2006-08-09 EP claimed
WO-2006061259-A2 CYTOTOXIC AGENTS COMPRISING NEW C-2 MODIFIED TAXANES AVENTIS PHARMA S.A. (FR) 2006-06-15 WO claimed
JP-5093071-A None JP disclosed
CN-111909069-B Degradable quaternary ammonium salt compound and preparation method and application thereof 安徽启威生物科技有限公司 2022-04-19 CN disclosed
CN-111909069-A Degradable quaternary ammonium salt compound and preparation method and application thereof 安徽启威生物科技有限公司 2020-11-10 CN disclosed
US-7598290-B2 Cytotoxic agents comprising new C-2 modified taxanes IMMUNOGEN, INC. (US) 2009-10-06 US disclosed
US-7422791-B2 Joint assemblies, methods for installing joint assemblies, and jointing compositions HALLSTAR INNOVATIONS CORP. (US) 2008-09-09 US disclosed
US-20070270482-A1 Cytotoxic Agents Comprising New C-2 Modified Taxanes AVENTIS PHARMA S.A. (FR) 2007-11-22 US disclosed
EP-1819687-A2 CYTOTOXIC AGENTS COMPRISING NEW C-2 MODIFIED TAXANES Aventis Pharma S.A. (FR) 2007-08-22 EP disclosed
WO-1995033736-A1 NEW TAXOIDS, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM RHONE-POULENC RORER S.A. (FR) 1995-12-14 WO disclosed
WO-1995033739-A1 NEW TAXOIDS, PREPARATION THEREOF AND PHAMACEUTICAL COMPOSITIONS CONTAINING THEM RHONE-POULENC RORER S.A. (FR) 1995-12-14 WO disclosed
WO-1995033738-A1 NEW TAXOIDS, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM RHONE-POULENC RORER S.A. (FR) 1995-12-14 WO disclosed
WO-1995026961-A1 PROCESS FOR THE PREPARATION OF 7-HYDROXY TAXANES RHONE-POULENC RORER S.A. (FR) 1995-10-12 WO disclosed
US-5395817-A N-pyridine substituted indoles IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1995-03-07 US disclosed
EP-0626946-A1 N-PHENYLINDOLE AND N-PYRIDYLINDOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS HERBICIDES ZENECA LIMITED (GB) 1994-12-07 EP disclosed
WO-1993015049-A1 N-PHENYLINDOLE AND N-PYRIDYLINDOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS HERBICIDES ZENECA LIMITED (GB) 1993-08-05 WO disclosed
JP-H0593071-A SILICONE-CONTAINING HIGH POLYMER LATEX ASAHI CHEM IND CO LTD 1993-04-16 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270482-A1 Cytotoxic Agents Comprising New C-2 Modified Taxanes CCAR2, MCL1, CYTH2 TDP1 1108/4885PMP22 2384/4885KDM4E 3979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.